Company: Pinewood Healthcare. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Pantoprazole 20mg, 40mg (as sodium sesquihydrate). Description: Light brownish yellow, oval, slightly biconvex tablets. Presentation: 20mg-28, €10.82; 40mg-28, €20.04. Indications: Zolepant 20mg: Treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing). Long-term management and prevention of relapse in [...]
Romep
Company: Rowex Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Omeprazole 10mg, 20mg, 40mg. Description: Hard gastro-resistant capsules containing yellowish brown granules.10mg: light brown marked OME10. 20mg: White marked OME20. 40mg: White cap, light brown body, marked OME40. Presentation: 10mg-28, €12.38; 20mg-28, €21.23; 40mg-14, €23.28. Indications: Duodenal ulcers, benign gastric ulcers, reflux oesophagitis (RO, [...]
Pantoprazole Niche
Company: Niche Generics Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Pantoprazole 20mg, 40mg. Description: Light brownish yellow, oval, slightly biconvex gastro-resistant tablets. Presentation: 20mg-28, €12.03; 40mg-28, €25.50. Indications: Pantoprazole Niche 20mg: Treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing). Long-term management and prevention of relapse in [...]
Pantium
Company: Clonmel Healthcare Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Pantoprazole 20mg, 40mg. Description: Yellow oval gastro-resistant tablets. Presentation: 20mg-28, €12.27; 40mg-28, €22.73. Indications: Pantium 20mg: Treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing); long-term management and prevention of relapse in reflux oesophagitis (RO); prevention of [...]
Pantoflux
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Pantoprazole 20mg, 40mg. Description: Elliptical biconvex light yellow (20mg) or dark yellow (40mg) gastro-resistant tablets. Presentation: Prices available on request. Indications: Pantoflux 20mg: Treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing); long-term management and prevention of [...]
Pantoprazole Teva
Company: TEVA Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Pantoprazole 20mg, 40mg (as sodium sesquihydrate). Description: Light brownish-yellow, oval, slightly biconvex gastro-resistant tablets. Presentation: 20mg-28, €12.27; 40mg-28, €22.72. Indications: Pantoprazole Teva 20mg: Treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing); long-term management and prevention of [...]
Pantup
Company: Rowex Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Pantoprazole 20mg, 40mg. Description: Yellow oval coated tablets imprinted 20 or 40 in black. Presentation: 20mg-28, €10.82; 40mg-28, €20.04. Indications: Pantup 20mg: Treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing); long-term management and prevention of relapse in [...]
Gaviscon Advance Oral Suspension Sachets
Company: Reckitt Benckiser. Legal category: OTC. Sport permitted. Active ingredient: Sodium alginate 100mg, potassium hydrogen carbonate 20mg per 1ml. Description: Off-white viscous suspension in sachets. Presentation: 10ml-20, €5.30. Indications: Symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals, or during pregnancy, or in patients with symptoms [...]
Listen to gut feelings about nocturnal GORD
Prof Fergus Gleeson on the importance of managing nocturnal GORD, a condition which can have serious complications if left untreated. Gastro-oesophage-al reflux disease (GORD) is the most common chronic disorder of the oesophagus. Population studies in the USA estimate that 20 per cent of the population experience GORD symptoms at least once per week It [...]